Samil Pharmaceutical Signs License Agreement for Arthritis Treatment with U.S. Pharmaceutical Company
[Asia Economy Reporter Ji Yeon-jin] Samil Pharmaceutical announced on the 30th that it has signed a license agreement with the US pharmaceutical company Biosplice Therapeutics, Inc for exclusive rights to the domestic approval and sales of the arthritis treatment Lorecivivint.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- Given Grants, Then Says "No Launch" ... Innovative Korean Technology Ultimately Forced Overseas
- [Breaking] Chairman Park Sookeun: "Possibility of Agreement Instead of Samsung Electronics Labor-Management Mediation Proposal"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
The total contract amount is 10 million dollars. The signing fee is 3 million dollars, and 7 million dollars will be paid according to each clinical and approval stage. Additionally, royalties will be paid based on the sales performance after the new drug is launched.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Cheaper Than Candy, Yet Impossible to Find... Fears of a 'Pediatric Medical Crisis' as Pharmaceutical Companies Halt Production [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/307/2026051910065268365_1779152813.jpg)
